Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:REPH Recro Pharma (REPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Recro Pharma Stock (NASDAQ:REPH) 30 days 90 days 365 days Advanced Chart Get Recro Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.47▼$2.1152-Week Range N/AVolume141,800 shsAverage Volume126,298 shsMarket Capitalization$117.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.Read More… Receive REPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address REPH Stock News HeadlinesFuji Pharma Co. Ltd.January 30, 2024 | wsj.comHere's what Wall Street expects from Recro Pharma's earnings reportNovember 7, 2023 | markets.businessinsider.com3 golden rules for dividends If you have any interest in building a great dividend portfolio, you will want to watch legend, Jack Carter’s briefing asap: The 3 Golden Rules for a Powerhouse Dividend Portfolio During this class, Jack walks you through all three of his “golden rules” and how they work. He even shares specific tickers that meet his criteria which you could consider adding to your portfolio today! And he explains each of his golden rules in detail.January 15, 2025 | Jack Carter Trading (Ad)US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsAugust 16, 2023 | theguardian.comWhat Wall Street expects from Recro Pharma's earningsAugust 9, 2023 | markets.businessinsider.comMankind Pharma Ltd (MNKI)August 3, 2023 | investing.comBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsJune 30, 2023 | bizjournals.comPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLJune 24, 2022 | benzinga.comSee More Headlines REPH Stock Analysis - Frequently Asked Questions How were Recro Pharma's earnings last quarter? Recro Pharma, Inc. (NASDAQ:REPH) issued its quarterly earnings data on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%. What other stocks do shareholders of Recro Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings3/01/2022Today1/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:REPH CUSIPN/A CIK1588972 Webwww.recropharma.com Phone(770) 534-8239Fax484-395-2471Employees185Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,370,000.00 Net Margins-15.15% Pretax Margin-15.09% Return on Equity-56.66% Return on Assets-11.14% Debt Debt-to-Equity Ratio2.27 Current Ratio3.24 Quick Ratio2.74 Sales & Book Value Annual Sales$75.36 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / BookN/AMiscellaneous Outstanding Shares56,424,000Free Float48,412,000Market Cap$117.93 million OptionableOptionable Beta1.08 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:REPH) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recro Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recro Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
